Home / Business and Economy / QuidelOrtho Q2 Beat, Slashes Full-Year Guidance Amid Headwinds
QuidelOrtho Q2 Beat, Slashes Full-Year Guidance Amid Headwinds
10 Aug
Summary
- QuidelOrtho's Q2 revenue surpassed analyst expectations with $630.9 million.
- Full-year revenue guidance was significantly reduced to $2.56 billion.
- China's IVD pricing uncertainty and softer respiratory environment impact performance.
QuidelOrtho's second quarter of 2026 saw revenue reach $630.9 million, surpassing market expectations. Despite this quarterly beat, the company significantly lowered its full-year revenue guidance. Management's updated forecast now stands at $2.56 billion at the midpoint, a notable decrease.
The reduction in guidance is attributed to persistent headwinds. These include pronounced weakness in China, stemming from uncertainty around new in-vitro diagnostics pricing guidelines, and a softer respiratory testing environment compared to the previous year.
Leadership expressed caution, modeling for continued muted respiratory activity and anticipating no immediate recovery in China. The company is maintaining a disciplined approach to forecasting and focusing on cost management and cash flow improvements amidst these external challenges.
